Clifford M. Samuel

Director at Antiva Biosciences

Clifford Samuel has 25+ years of commercial leadership experience in the biopharmaceutical industry, with more than two decades at Gilead Sciences in leadership roles across sales, managed markets, and global commercial operations, including Senior Vice President, Global Patient Solutions, with responsibility for more than 140 countries. Propelled by his mission to ensure large-scale access to Gilead’s life-saving medicines, Clifford enabled the delivery of medicines to more than 18 million people in emerging markets, while increasing revenue by billions. He spearheaded Gilead’s entry into generic licensing agreements with companies in China, India and South Africa that created a competitive market for generic HIV and hepatitis B & C medicines. Clifford has been recognized for pioneering new and developing fields of technology, making major advancements in traditional fields of engineering, and developing and implementing innovative approaches to engineering education. A graduate of the New Jersey Institute of Technology (NJIT) with a BS in Mechanical Engineering, he received an Honorary PhD from his alma mater and sits as an NJIT Honor Program Board Member. He is also the recipient of an Edward F. Weston Medal for Professional Achievement and was inducted into the National Academy of Engineers in 2019.

Location

San Francisco, United States

Links


Org chart

This person is not in the org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


Antiva Biosciences

Antiva Biosciences, Inc. is a clinical stage biopharmaceutical company developing novel, topical therapeutics for the treatment of diseases caused by HPV infection. They aim to stop cancer before it starts by treating the pre-cancerous lesions caused by HPV.


Industries

Employees

11-50

Links